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Background: α-Synuclein (α-syn) plays a central role in the pathogenesis of synucleinopathies, a group of
neurodegenerative disorders that includes Parkinson disease, dementia with Lewy bodies and multiple system
atrophy. Several findings from cell culture and mouse experiments suggest intercellular α-syn transfer.
Results: Through a methodology used to obtain synthetic mammalian prions, we tested whether recombinant
human α-syn amyloids can promote prion-like accumulation in neuronal cell lines in vitro. A single exposure to
amyloid fibrils of human α-syn was sufficient to induce aggregation of endogenous α-syn in human neuroblastoma
SH-SY5Y cells. Remarkably, endogenous wild-type α-syn was sufficient for the formation of these aggregates, and
overexpression of the protein was not required.
Conclusions: Our results provide compelling evidence that endogenous α-syn can accumulate in cell culture after
a single exposure to exogenous α-syn short amyloid fibrils. Importantly, using α-syn short amyloid fibrils as seed,
endogenous α-syn aggregates and accumulates over several passages in cell culture, providing an excellent tool for
potential therapeutic screening of pathogenic α-syn aggregates.
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α-Synuclein (α-syn) is a key player in the pathogenesis of a
group of neurodegenerative diseases defined as synucleino-
pathies, including Parkinson disease (PD), dementia with
Lewy bodies (DLB), and multiple system atrophy (MSA).
The discovery that aggregated α-syn is the major compo-
nent of Lewy bodies (LBs) [1] indicates a role of α-syn in
PD. Neurons containing LBs are the hallmark of PD and
DLB, whereas in MSA α-syn is deposited in oligodendro-
cytes referred to as glial cytoplasmic inclusions (GCIs)
[2-4]. In its aggregated form, α-syn is enriched in β-sheet
structure, orderly organized into oligomers or amyloid
fibrils [5]. As such, many amyloid proteins are characteris-
tic of specific neurodegenerative disorders, for instance
Alzheimer disease (AD) and prion diseases. For several* Correspondence: legname@sissa.it
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unless otherwise stated.decades it has been speculated that the key to understand-
ing age-related neurodegenerative disorders may be found
in the unusual biology of prion diseases. This hypothesis is
being increasingly supported by experimental evidence.
The self-propagation of amyloid-β (Aβ) aggregates is also
known from in vitro studies [6] and inoculation experi-
ments [7]. However, only recent experiments using genet-
ically modified rodents have established that Aβ can be
induced to deposit in brain by a prion-like mechanism. In-
tracerebral injection of Aβ-rich brain extracts from AD
patients or from aged APP-transgenic mice stimulated the
premature formation of plaques in these models [8,9]. Aβ
lesions in APP transgenic mice are also inducible by injec-
tions of pure, synthetic human Aβ fibrils, although syn-
thetic seeds are less powerful than aggregates formed
within the living brain. Like prions, Aβ seeds vary in size
from small, soluble, protease-sensitive aggregates to large,
insoluble, protease-resistant fibrils [10].
Accumulating experimental data indicate that the seed-
ing principle also applies to other pathogenic proteins that
form amyloid-like inclusions within the cells. This is also
the case of α-syn which, in its misfolded state, formsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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arise first in the brainstem and then spread to telence-
phalic structures [12]—a dynamics indicative of prion-like
spread of protein aggregation. Numerous studies have
shown cell-to-cell transmission of soluble or aggregated α-
syn, both in cultured cells and in mouse brains, resulting
in α-syn aggregation and neuronal dysfunction in the re-
cipient cells [6,13-15]. Importantly, injections of synthetic
(human or mouse) α-syn fibrils also induce the recruit-
ment of endogenous soluble α-syn protein to form LB-like
pathology and neuronal degeneration in primary cell cul-
ture [16] and in non-transgenic (wild type) host mice
[17,18]. Lastly, Melki et al. have shown that two different
α-syn polymorphs (fibrils and ribbons) exhibit marked dif-
ferences in their propensity to penetrate the cells, as well
as in their toxicity and seeding aggregation in cells, sug-
gesting the existence of different α-syn strains [19].
On the basis of these findings, we considered the pos-
sibility that recombinant human α-syn could acquire
prion-like properties, once it is converted into a β-sheet-
rich structure, and determine the fate of endogenous α-
syn in human immortalized cell lines.
Results
Aggregation properties and structural characterization of
recombinant α-syn assemblies
Evidence in literature shows that, under different experi-
mental conditions, the formation of LB-like inclusions
can be induced in cultured cells overexpressing human
α-syn [20]. To test whether the same process may be in-
duced in the non-transfected human SH-SY5Y cell line
we applied different α-syn fibril assemblies to the cell
culture.
First, we expressed in bacteria and then purified recom-
binant human α-syn protein (Additional file 1: Figure S1)
either as wild-type sequence or tagged with a FLAG epi-
tope, and established a protocol to induce structured
amyloid assemblies as previously shown for the produc-
tion of mammalian synthetic prions [21] (Figure 1A). Be-
cause various intermediate forms of α-syn develop during
the process of fibril formation, we decided to collect β-
sheet-rich structures at different time points during the
fibrillization assay: (i) at the early inflection of the sigmoid
curve; (ii) at the middle portion of the curve; and (iii) at
plateau (collection times are highlighted by red arrows in
Figure 1A).
We reasoned that these diverse β-sheet-rich assem-
blies might differ in quaternary structure. As predicted,
atomic force microscopy measurements showed diverse
assemblies: oligomers, and short and long amyloid fi-
brils (Figure 1C). From the statistical analysis of the
three different preparations (Figure 1D) we identified
three different assemblies enriched in: (i) oligomeric
structure, indicating spherical, ring-like characteristics;(ii) short fibrils, the protofibril-like structure, and (iii)
long fibrils (Additional file 2: Table S1 lists all height
and length values observed).
Toxicity of α-syn aggregates in cells
We assessed the cytotoxicity of equal concentrations of
three different α-syn preparations on human neuroblast-
oma SH-SY5Y cells using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. This cell
survival assay showed that there was no statistically signifi-
cant difference among the various forms of α-syn prepara-
tions in the cell line used (Figure 2A). A comparison of
the toxicity of α-syn short and long fibrils does not reflect
any specific toxicity, except for the well-known slightly
higher toxicity of oligomeric species [22-24] (74.7% viable
cells in SH-SY5Y cells).
Effects of exposure of human neuroblastoma cell lines to
different α-syn assemblies
We adopted different strategies to validate the observation
that exogenously added assemblies can enter and be incor-
porated into cells. Either recombinant human α-syn or
FLAG-tagged recombinant human α-syn protein was
employed. The use of the FLAG-tagged protein allows the
detection of exogenously added protein assemblies. In-
deed, after seven days in culture only short amyloid fibrils
were able to enter the cells and promote the recruitment
of endogenous α-syn into aggregates, while oligomers and
long fibrils could not. As a matter of fact, to effectively
serve as a seed for aggregation, exogenously added assem-
blies must first enter the cells and persist for a sufficient
period in cellular compartments accessible to the en-
dogenous α-syn protein. A single exposure of β-sheet-rich
structures of recombinant human α-syn—which we define
as short amyloid fibrils—was sufficient to permit the ag-
gregation of endogenous α-syn in non-transfected human
neuroblastoma SH-SY5Y cells. The SH-SY5Y cells exposed
to short amyloid fibrils of recombinant human FLAG-
tagged α-syn were stained with either an anti-human α-syn
antibody or an anti-FLAG immunoglobulin (Figure 2B).
The immunoreactivity was mostly cytosolic, with co-
localization of anti-FLAG and anti-human α-syn antibody.
The result yielded by immunofluorescence was verified by
biochemical experiments, which confirmed the increase of
endogenous α-syn (Figure 2C).
Next, we analyzed the aggregation of the endogenous
α-syn in serial cellular passages. For this purpose we in-
cubated the protein preparation with the SH-SY5Y cells
only at passage 0 (p0, Figure 3), and at each passage we
measured the levels of α-syn using immunofluorescence
(Figure 3, graph). Only a residual staining of endogenous α-
syn could still be observed in the subsequent passage (p1)
and no staining was detectable in the ensuing two passages
(p2 and p3). Surprisingly, aggregates of endogenous α-syn
Figure 1 In vitro conversion and AFM characterization of three different recombinant α-syn assemblies. Kinetics for the formation of
β-sheet-rich assemblies: human α-syn oligomer (dotted black line), human α-syn short fibrils (red triangle line) and human α-syn long fibrils (gray
dotted line), and control (gray solid line). (A) Red arrows indicate the collection time of the aggregates. (B) The lag phase, in hours, of all β-sheet
structure preparations was measured using Thioflavin T assay. The lag phase distribution of α-syn and FLAG-α-syn amyloid preparations showed
no difference (P > 0.5), indicating that the presence of FLAG-tag did not affect fibril formation. (C) AFM imaging analysis was performed at the
end of the fibrillization reactions. AFM scan topographical images of α-syn deposited on mica surface. (D) The size of particles was measured: the
typical height of α-syn oligomers was 0.65 ± 0.11 nm, the height of short and log fibrils was 2.79 ± 1.20 nm, and 6.08 ± 1.38 nm, respectively. The
values are the average calculated on 20 fibrils. The error is the standard deviation.
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observed many small, dispersed aggregates, while at pas-
sages p5 and p6 we began to observe larger aggregates and
perinuclear inclusions in the cytoplasm of SH-SY5Y cells
(Figure 3, white arrows). We performed additional passages
(up to passage 12) and in each one a sustained aggregation
of endogenous α-syn was still present. Therefore, the in-
fected SH-SY5Y cells are able to promote, upon subpas-
saging, stable aggregation of endogenous α-syn. This
accumulation occurs at the protein level since PCR ana-
lysis confirmed that the levels of α-syn transcripts were
not altered after infection (Figure 3B).
Interestingly, the endogenous aggregates of human α-syn
in the SH-SY5Y cell line were Thioflavin S (ThS)-positive
(Figure 4). This dye binds to β-sheet-rich structures such as
amyloids, confirming that the aggregates induced at sixth
passage contained significant β-sheets, like LBs do. Thus,
the fact that these α-syn aggregates share hallmark featuresof PD-like LBs led us to conclude that α-syn short amyloid
fibrils seed and recruit normal, endogenous α-syn to form
pathologic aggregates in the SH-SY5Y cell line.
Short amyloid fibrils of α-syn induce accumulation earlier
in transfected SH-SY5Y cells
We performed similar experiments using a human neuro-
blastoma SH-SY5Y cell line stably overexpressing human α-
syn (Additional file 3: Figure S2). Upon infection with short
amyloid fibrils of α-syn and after six passages in cell culture,
we observed stronger staining and, most importantly, the
presence of several spots of α-syn throughout the cytosol.
The accumulation of α-syn was confirmed using the west-
ern blot technique at p5 in both SH-SY5Y that overexpress
α-syn and the non-transfected cells (Figure 5B). This sug-
gests that α-syn short amyloid fibrils are able to seed aggre-
gation of overexpressed α-syn in this cellular model. Due to
the already high levels of α-syn in SH-SY5Y cells that
Figure 2 Cytotoxicity, extracellular α-syn uptake and recruitment of endogenous α-syn in SH-SY5Y cells. (A) Cells were treated with
5 μg/mL α-syn oligomers, short, and long fibrils for 24 hours. Results are mean ± st. dev. of three independent experiments performed in six
replicas. (B) Internalization of FLAG-α-syn amyloids into neuroblastoma cells SH-SY5Y. α-Syn deposition (green) was detected by anti-human
α-syn antibody. Immunofluorescence was performed on cells exposed to FLAG-α-syn amyloids (oligomers, short amyloid fibrils and long fibrils)
for 7 days. Bar, 11.9 μm. (C) Formation of endogenous α-syn deposits induced by extracellular α-syn short amyloid fibrils. Cells were treated for
7 days. Western blot analysis was performed using the α-syn (C-20)-R antibody, which recognizes endogenous human α-syn in SH-SY5Y cells.
The nuclei (blue) were stained with DAPI. Scale bars, 11.9 μm.
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endogenous α-syn aggregates upon infection with recom-
binant assemblies was evident earlier (p2) compared with
non-transfected SH-SY5Y cells (p4) (Additional file 3: Figure
S2). Moreover, these aggregates in SH-SY5Y overexpressing
α-syn at passage p6 were ThS-positive (Additional file 4:
Figure S3). Furthermore, the sequential extraction with 1%
Triton X-100 lysis buffer followed by 2% SDS lysis buffer
confirmed that the endogenous aggregates of α-syn are in-
soluble in these buffers. The cells treated with short amyl-
oid fibrils and passaged up to p6 exhibited a significantamount of Triton X-100 insoluble α-syn and high-
molecular-weight species (HMW), which required SDS
buffer for solubilization (Figure 5C). We observed weak
signals in the SDS supernatant fraction. On the contrary,
in the pellet fraction we detected bands in the stacking
part of the SDS-PAGE gel, which are comparable to those
of short amyloid fibrils formed in vitro (Figure 5A).
Endogenous α-syn aggregates display LB-like properties
To further characterize endogenous α-syn aggregates,
the cell lines were probed with an antibody specific for
Figure 3 Infection of the non-transfected SH-SY5Y cells with α-syn short amyloid fibrils and sub-passing over time. (A) Cells were
infected with recombinant human FLAG-α-syn short fibrils. Cells were cultured on coverslips for each passage (p0 to p6). The deposition of exogenous
short amyloid fibrils FLAG-α-syn (red) was detected by anti-FLAG antibody. Human endogenous α-syn detected by anti-human α-syn (C-20)-R antibody
(green). The nuclei were stained with DAPI (blue). Bar, 12 μm. On the right p4, p5, and p6 zoomed images. Corrected total cell fluorescence (CTCF) from
immunofluorescence imaging shows the induction of endogenous α-syn in SH (neuroblastoma SH-SY5Y cell line) infected with human α-syn short
amyloid fibrils during the passages (bottom panel). The analysis was performed on at least 150 cells, n = 3, ***p < 0.005. Values are mean ± SD. (B) PCR
analyses directed to α-syn using the total RNA extracted from non-transfected SH-SY5Y cells. Mix, RT-, S. Mix: negative controls, pET11A: positive control,
SH-SF p6: SH-SY5Y cells passaged six times after exposure to short amyloid fibrils, SH: SH-SY5Y cells not treated with short amyloid fibrils. α-Syn was
detected after 25 cycles and did not show any significant difference in transcripts before and after infection with short amyloid fibrils of recombinant α-syn.
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post-translational modification of α-syn aggregates has
been found in LBs of PD brains. Moreover, P-S129 α-synhas been reported to accumulate in the nuclei of α-syn
transfected cells [25], and in Tg mice that express hu-
man α-syn [26]. A single-staining immunofluorescence
Figure 4 Thioflavin-S (ThS) positive staining of endogenous α-syn aggregates. SH-SY5Y cells were infected with recombinant human α-syn
short amyloid fibrils (SF: short amyloid fibrils of α-syn) and sub-passed at sixth passage (p6). The deposition and level of α-syn (red) in α-syn-infected cell
lines after six passages were detected by anti-α-syn antibody (Additional file 6: Table S2). The colocalization was observed between the ThS signal
(yellow) and anti-human α-syn antibody (red). The nuclei (blue) were stained with DAPI. Scale bars, 12 μm.
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cleus after nine passages upon infection (SH-SFp9 and
SH-OE SFp9, Figure 6) in both non-transfected and trans-
fected SH-SY5Y cells, compared to control non-infected
cells (Figure 6, lower panel). Since exogenous recombinant
short amyloid fibrils are not phosphorylated in vitro, these
modifications occur de novo within the cell after infection
and passaging. In addition, the cytoplasm of several α-syn-
infected SH-SY5Ycells contained α-syn aggregates (Figure 6,
top panel). Quantitative analysis showed that the number
of cells with these cytoplasmic inclusions was remarkably
higher in amyloid-infected cells compared to non-infected
cells (54.8% vs. 7.7%, p < 0.001) (Figure 6B, bottom left).
Thus, we concluded that although overexpression of α-syn
induces aggregation, this occurs to a much greater extent
when combined with infection. Interestingly, in amyloid-
infected cells we found the same increase in phosphorylated
aggregates compared to transfected cells (44.7% vs. 9.2%,
p < 0.001) (Figure 6B, bottom right) indicating that most
α-syn aggregates induced by short amyloid fibrils are
phosphorylated.Together, these observations indicate that the en-
dogenous α-syn aggregates in this cell culture model ex-
hibit LB-like defining features.
Discussion
Immortalized cell lines and primary-cultured cells are
commonly used in the research of synucleinopathies.
Volpicelli-Daley et al. [16] have reported a seeded inclu-
sion formation in primary neuronal cultures that did not
overexpress α-syn, and Sacino et al. [27] have investigated
the aggregation process in primary mixed neuronal-glial
cultures using recombinant wild-type α-syn and PD-
linked mutations (A53T and E46K). Nevertheless, the
drawback of employing primary cell models is that they
have a limited use for transmission experiments. More-
over, the cellular populations might be altered during re-
peated sub-passaging. This is one reason why we focused
on immortalized cell lines, as they yield more homogenous
cell preparations, cells can be passaged for long periods,
and they harbor a sufficient quantity of samples for bio-
chemical analyses. Indeed, here we show that one defined
Figure 5 Aggregation of α-syn in dopaminergic human cell lines infected with recombinant human α-syn short amyloid fibrils and
sub-passaged over five passages (p5). (A) Western blot of different assemblies formed in vitro. (B) Western blot of cell lysates (SH: SH-SY5Y cells;
SH-OE SH-SY5Y overexpressing human α-syn); Ctrl: non-treated cells. SFp5: α-syn short amyloid fibril-infected cells at fifth passage. HMW: High molecular
weight aggregates. (C) Western blot analysis of aggregated SH-OE cell lysates treated with α-syn short amyloid fibrils, and non-treated (Ctrl); Total: total
cell lysates. Sequential extraction of α-syn aggregates in 1% Triton X-100 lysis buffer (S-TX), followed by 2% SDS lysis buffer (S). (P): a pellet fraction after
the pellet was treated with 2% SDS. Anti-human α-syn (C-20)-R antibody was used (Additional file 6: Table S2).
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endogenous α-syn to aggregate, thus supporting the hy-
pothesis that α-syn pathology can spread via a prion-like
self-templating mechanism. This finding is a shared fea-
ture with other cell culture models that are permissive to
prion replication, such as neuroblastoma N2a cells [28].
This infected cell culture model has provided valuable in-
sights into the biogenesis of the scrapie prion protein
(PrPSc) in terms of subcellular localization, conversion, and
physiopathological consequences. Therefore, using the im-
mortalized SH-SY5Y cell line, which replicates α-syn aggre-
gates, is important to better understand the mechanism
involved in α-syn aggregation. We focused our attention on
non-transfected SH-SY5Ycells, and these findings were also
confirmed in another cell line that does not overexpress α-
syn protein. The GT1 cell line [29] was treated with short
amyloid fibrils of recombinant human α-syn, and we ob-
served the same results, indicating that this aggregation
phenomenon extends to multiple cell types, even to those
that do not overexpress α-syn (Additional file 5: Figure S4).These cell cultures will allow us to study the mechanism of
cellular uptake of fibrils (p0), the conversion mechanism of
endogenous α-syn protein into aggregates (from p4), and
their sub-cellular localization.
Conclusions
In this study we characterized three different fibril assem-
blies of recombinant α-syn protein (oligomers, short fibrils,
and long fibrils) and evaluated their effect on immortalized
cell lines. Our findings show that recombinant human α-
syn can adopt a conformation (i.e., short amyloid fibrils)
able to recruit cellular α-syn into aggregates that can repli-
cate and accumulate in vitro in non-transfected cells. Al-
though we used synthetic recombinant assemblies, and not
the aggregates from brain homogenates either from PD pa-
tients or transgenic mice, we observed prolonged and sus-
tained aggregation and accumulation of endogenous α-syn
in non-transfected and transfected SH-SY5Y cell lines. Our
findings point to α-syn short amyloid fibrils as the patho-
logical species of α-syn aggregates primarily involved in the
Figure 6 Short amyloid fibrils induce the formation of phosphorylated α-syn aggregates over passages. (A) Presence of phosphorylated
α-syn aggregates in SH-SY5Y overexpressing α-syn (SH-OE, top left panel). From left to right: neuroblastoma SH-SY5Y (SH), SH-SY5Y infected with human
α-syn short amylod fibrils at passage 9 (SH-SFp9), SH-SY5Y overexpressing α-syn (SH-OE) and SH-SY5Y overexpressing α-syn-infected with human α-syn
short amylod fibrils at passage 9 (SH-OE-SFp9). Cells were immunolabeled with anti-α-syn antibody (green, upper panel) or anti-phospho S129 α-syn
Ab59264 (green, lower panel). Scale bars, 5 μm. Arrows point at α-syn aggregates. Images are representative of at least three independent experiments.
(B) High percentage of phosphorylated α-syn aggregates in SH-SY5Y α-syn-infected cells. Bar diagram showing quantification of α-syn aggregates (left)
and phospho S129 α-syn aggregates (right) in SH-SY5Y α-syn cells and SH-SY5Y α-syn-infected cells. ***p < 0.001 (Student t test, n > 150 cells counted for
each condition per experiment). Error bars represent the SEM.
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hypothesis that the sequence of events leading to LB for-
mation can be recapitulated in cultured cells. In summary,
we developed a new approach for the study of α-syn aggre-
gates in cell culture. The advantage of our system is that it
can be employed for prolonged experimental periods since
the accumulation of α-syn is sustained over time. This ap-
proach systematically minimizes the possibility of clonal ar-
tifacts and represents a valid tool for potential therapeutic
screening that targets pathologic α-syn aggregates.
Methods
Cell lines
The GT1-1 cells were obtained from the laboratory of Pro-
fessor Krister Kristensson, Department of Neuroscience,
Karolinska Institutet Stockholm, Sweden, following an
MTA agreement with Dr. Pamela Mellon of the University
of California, San Diego, USA. This line is often used inprion biology and it is established from gonadotropin
hormone-releasing neurons immortalized by genetically
targeted tumorigenesis in transgenic mice [29]. The SH-
SY5Y cell line is a thrice-cloned sub-line of SK-N-SH cells,
which were originally established from a bone marrow bi-
opsy of a neuroblastoma patient with sympathetic adrener-
gic ganglial origin [30]. GT1 cells were seeded in 10-cm
plates containing 10 mL of Dulbecco’s modified Eagle’s
medium (DMEM) culture media, supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin-streptomycin.
SH-SY5Y normal cells were cultivated in 10-cm plates, con-
taining 10 mL of minimal EMEM: Ham F12 (1:1) culture
media, supplemented with 15% FBS, 1% non-essential
amino acids, 0.5% L-glutamax, 1% penicillin-streptomycin
and 1% G-418 (only for SH-SY5Y wild-type cells trans-
fected for overexpressing α-syn). The cells were grown at
37°C in 5% CO2 to 95% confluence for 1 week before split-
ting at 1:10 for further cultivation.
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The cytotoxic effect of α-syn fibrils was assessed by
measuring cellular redox activity with 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
Briefly, 100,000 SH-SY5Y and GT1 cells/well were cul-
tured in a 96-well microtiter plate and treated with α-
syn oligomers, short fibrils and long fibrils (suspended
by vortexing). Following a 24-h incubation, the cytotoxic
effect was assessed by measuring cellular redox activity,
following the manufacturer’s (Sigma) instructions.
Expression and purification of recombinant human α-syn
Expression and purification of recombinant human α-syn
were performed in accordance with the method previously
described [30]. Briefly, the human α-syn gene was cloned
and expressed in pET11a vector using BL21 (DE3) E. coli
strain. Expression of α-syn was obtained by growing cells in
Luria-Bertani broth medium with 100 mg/mL ampicillin at
37°C until an O.D.600 of about 0.6, followed by induction
with 0.6 mM isopropyl β-D-thiogalactoside (IPTG) for
5 hours. The protein was purified according to the method
of Huang et al. [31].
α-syn amyloid preparations
All solutions were sterilized by filtration through a 0.22-
μm filter prior to each assay run. Reactions were prepared
in a 96-well black plate (BD Falcon), and each well con-
tained 200 μL of reaction solution [1.5 mg/mL recombin-
ant human α-syn, 100 mM NaCl, 10 μM Thioflavin T
(ThT) in 20 mM Tris–HCl pH 7.4]. Each sample analysis
was performed in fifteen replicates. Each well contained
one 3-mm glass bead (Sigma). The plate was covered with
sealing tape (Fisher Scientific), incubated at 37°C under
continuous shaking, and read on SpectraMax M5 fluores-
cence plate reader (Molecular Devices) by top fluores-
cence reading every 5 min at excitation of 444 nm and
emission of 485 nm.
AFM analysis
AFM analysis was performed in accordance with the
method previously described [32]. Three to five μL of fibril
solution was deposited onto a freshly cleaved piece of mica
and left to adhere for 30 min. Samples were then washed
with distilled water and blow-dried under a flow of nitro-
gen. Images were collected at a line scan rate of 0.5-2 Hz in
ambient conditions. The AFM free oscillation amplitudes
ranged from 25 nm to 40 nm, with characteristic set points
ranging from 75% to 90% of these free oscillation ampli-
tudes. AFM data were analyzed with Gwyddion (gwyddion.
net) and SPIPTM (www.imagemet.com) software.
α-syn amyloid solution for cell infection
The α-syn amyloid solution was transferred from the 96-
well plate into a 1.5 mL Eppendorf tube and collectedunder sterile conditions. The solution was ultracentri-
fuged at 100,000 g for 30 min at 4°C (Beckman Coulter).
Pellets were resuspended in 1X PBS and then sonicated
(Branson 2510) for 5 min prior to adding to the cultured
cell plate.
α-syn fibril infection in cell lines
Three hundred μg of α-syn amyloids was added to GT1
and SH-SY5Y cell plates (10 cm-plate) and exposed in the
cell culture media for 7 days before the next splitting and
media change. Cells were split and maintained for six add-
itional passages. Cell lysates were collected at each passage
for Western blotting and immunofluorescence studies.
For immunofluorescence of amyloids internalization, cells
were cultured in 12-well plates with coverslips; 30 μg of α-
syn amyloids was added to the cell culture media and in-
cubated for 7 days.
Detection of α-syn aggregates in infected cells and
analysis by Western blotting
The total protein content of samples was measured by
bicinchoninic acid assay (BCA) (Pierce). Fifty μg of cell ly-
sates protein was used and 5X loading buffer was added in
a 1:5 ratio. The samples were boiled for 5 min at 100°C,
loaded onto a 10% Tris-Glycine SDS-PAGE gel, and trans-
ferred overnight onto Immobilon P PVDF membranes
(Millipore). Membranes were blocked by 5% nonfat milk,
incubated with 0.4 μg/mL rabbit polyclonal anti-α-syn anti-
body (Santa Cruz) followed by incubation with goat anti-
rabbit IgG F(ab)2 fragment conjugated with horseradish
peroxidase. Blots were developed with the enhanced chemi-
luminescent system (ECL, Amersham Biosciences) and
visualized on Hyperfilm (Amersham Biosciences). To
analyze α-syn aggregation in cell samples, cells were
scraped in TBS buffer containing 1% Triton X100, protease
cocktail inhibitors and phosphatase inhibitor. After sonic-
ation (Sonicrep 150) with 10 amplitude microns for 3 times
(30 seconds of sonication and 30 seconds intermediate
stop) cells were centrifuged at 2000 RPM for 5 min before
the protein was quantified. Fifty μg of sample was centri-
fuged at 100,000 g for 30 min. Supernatant (in term S-TX)
was collected and the pellets were resuspended in 2% SDS.
Samples in 2% SDS were centrifuged, supernatant (S) and
pellet (P) were collected. All the fractions were added to
loading buffer 5X in ratio 1:5 and prepared similarly for
Western blotting.
Reverse transcribed–polymerase chain reaction
Total RNA was extracted from cultured cells using the
TrizolW Reagent (Life Technologies) extraction method.
From 1 μg of total RNA, cDNA was synthesized using 200
units MoMuLV-reverse transcriptase (SuperScrip™ III RT;
Life Technologies), oligo (dT) primers and 1 μl 10 mM
dNTP Mix in a final volume of 13 μl. Ten microliters of
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tive PCR analysis. The following primer pairs were used for
α-syn: Hu_Syn_FW 5′-ATGGATGTATTCATGAAA-3′,
Hu_Syn REV 5′-TTAGGCTTCAGGTTCGTA-3′. PCR
amplification was conducted using the PhusionW High-
Fidelity DNA Polymerase protocol, under the following
conditions: initial denaturation at 98°C for 30s, 10s at 98°C,
30s at 45°C and 30s at 72°C for 25 cycles, followed by 10
min at 72°C. After amplification, 10 μl aliquots were elec-
trophoresed in 1.5% agarose gel, followed by photographic
recording of the gel stained with ethidium bromide.
Immunocytochemistry and ThS staining of α-syn fibril-
infected cells
Cells on coverslips were washed with PBS and fixed with
4% paraformaldehyde, then washed twice, 15 min/time
with PBS and blocked in blocking buffer [5% normal
goat serum (NGS) in PBS + 0.3% Triton] for 1 hour. For
Thioflavin S (ThS) staining, fixed cells were incubated
with 0.025% of the fluorophore (Sigma) for 8 min and
washed three times with 80% ethanol for 5 min each
time, prior to the antibody incubations. Fluorescence im-
munocytochemistry was performed using the primary
and secondary antibodies listed in Additional file 6:
Table S2. Primary antibodies were made up in 1% block-
ing buffer and PBS. After incubation, the cells were
washed 5 times for 5 min/time with PBS; secondary anti-
bodies were incubated in 1% blocking buffer and PBS for
45 min. Finally, cells were washed 5 times, 5 min/time
with PBS, and counterstained with DAPI to reveal nu-
clei, then mounted in Vectashield Mounting Medium.
Cell coverslips were stored at 4°C for confocal fluores-
cence microscopy. The fluorescence was measured in at
least 10 randomly chosen observation fields for each ex-
perimental condition using Leica SP5 confocal laser-
scanning microscope. The increase in fluorescence was
measured calculating CORRECTED TOTAL CELL
FLUORESCENCE (CTCF) using the formula: CTCF =
Integrated density – (Area of selected cell X Mean
fluorescence of Background readings) using the ImageJ
1.47 Software (NIH). Quantification experiments were
carried out independently at least three times; more
than 150 cells were counted for each condition. Individ-
ual differences were assessed using individual student’s
t-tests in GraphPad Prism software (San Diego, CA).
Data are shown as mean ± standard deviation (SD).
Immunofluorescence microscopy analysis of
phosphorylated aggregates
All dopaminergic neuroblastoma SH-SY5Y cells were
grown on ibidi dishes (Biovalley) for microscopy. After
washing in PBS, cells were fixed using 4% (w/v) parafor-
maldehyde (Sigma) in PBS for 15 min and permeabilized
with 0.01% Triton X-100 (Sigma) in PBS for 3 min, washedand blocked in 2% Bovine serum albumin (Sigma) in PBS
for 20 minutes. Cells were immunostained using anti-α-syn
(Santa Cruz Biotechnology, INC) and anti-phospho S129
α-syn (Abcam) followed by secondary antibody coupled to
Alexa 488 (Invitrogen). Cells were mounted in Aqua Poly/
Mount (Polysciences) and pictures were acquired using
white field Axiovision microscope (Zeiss) with a 63x object-
ive. Quantification experiments were carried out independ-
ently at least three times; more than 150 cells were counted
for each condition. Individual differences were assessed
using individual student’s t-tests in GraphPad Prism soft-
ware (San Diego, CA). Data are shown as mean ± standard
error of the mean (SEM).Additional files
Additional file 1: Figure S1. Plasmids used for expressing human α-syn
and FLAG-human α-syn in E. coli BL21(DE)3. (A) Homology comparison
between mouse α-syn and human α-syn, (B) highlighting amino acid
substitutions. (C) Typical chromatogram obtained from human α-syn
protein purification by anion-exchange chromatography with HiTrap Q
Sepharose Fast Flow column. The protein was eluted with a 0–0.5 M NaCl
gradient in 20 mM Tris pH8.0. Fractions B7-B2 correspond to purified
protein. (D) Expression of recombinant human α-syn protein, 15% SDS-PAGE.
Lane 1 and 5, molecular mass marker; lane 2, whole cell extract before IPTG
induction; lanes 3 and 4, cell extract after IPTG induction: 5 hours (lane 3),
overnight induction (lane 4); lane 6, purified α-syn protein.
Additional file 2: Table S1. Summary of dimensions of the three α-syn
amyloid preparations.
Additional file 3: Figure S2. Infection of the transfected SH-SY5Y cells
with α-syn short amyloid fibrils and sub-passing over time. The SH-SY5Y cells
that stably overexpress human wild-type α-syn (SH-OE) were infected with
recombinant human FLAG-α-syn short fibrils. Cells were cultured on coverslips
for each passage (P0 to P6). The deposition of exogenous short amyloid fibrils
FLAG-α-syn (red) was detected by anti-FLAG antibody. Human endogenous
α-syn detected by anti-human α-syn (C-20)-R antibody (green). The
nuclei were stained with DAPI (blue). Bar, 12 μm. Corrected total cell
fluorescence (CTCF) from immunofluorescence imaging shows the
induction of endogenous α-syn in SH (neuroblastoma SH-SY5Y cell
line) infected with human α-syn short amyloid fibrils during the
passages (bottom panel). The analysis was performed on at least 150
cells, n = 3, ***p < 0.005. Values are mean ± SD.
Additional file 4: Figure S3. Thioflavin-S (ThS) positive staining of
endogenous α-syn aggregates in stably transfected SH-SY5Y cell line.
The SH-SY5Y cells that overexpress wild-type human α-syn (SH-OE) were
infected with recombinant human α-syn short amyloid fibrils (SF: short
amyloid fibrils of α-syn) and sub-passaged at sixth passage (p6). The
deposition and level of α-syn (red) in α-syn-infected cell lines after
six passages were detected by anti-α-syn antibody (Additional file 6:
Table S2). The colocalization was observed between the ThS signal
(yellow) and anti-α-syn antibody (red). The nuclei (blue) were stained
with DAPI. Scale bars, 12 μm.
Additional file 5: Figure S4. The treatment with short amyloid fibrils in
another cell line (GT1 cells) induces the same behavior. (A)
Immunofluorescence images show the induction of endogenous mouse
α-syn in GT1 cells after infection with human α-syn short amyloid fibrils
over four passages.The detection of exogenously added short amyloid
fibrils was performed using an anti human α-syn antibody [LB 509] (red).
Mouse endogenous α-syn was detected by anti mouse α-syn antibody
D37A6 (green). The nuclei were stained with DAPI (blue). Bars of Ctrl, p0
and p1 are 12 μm; bars of p2, p3, p4 are 24 μm. The graph shows the
analysis of the relative corrected total cell fluorescence (CTCF) of
endogenous α-syn in GT1 cells infected with human α-syn short amyloid
fibrils during the passages. The analysis was performed on at least 150
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http://www.biomedcentral.com/1471-2202/15/69cells, n = 3, ***p < 0.005. Values are mean ± SD. (B) ThS staining of
endogenous aggregated in GT1 cells. (C) Western blotting of cell lysates
exposed to anti-α-syn antibody; SFp5: human α-syn short amyloid
infected cells at fifth passage.
Additional file 6: Table S2. Antibodies used in this study.
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